New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)
Dec 08, 2017•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast